Details of the Drug Combination

General Information of Drug Combination (ID: DCARNK0)

• Drug Combination Name: Valproic Acid + Tolazoline
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Valproic Acid (DMS49KH): Small molecular drug
  Tolazoline (DMI40NL): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 0.51
  Bliss Independence Score: 0.51
  Loewe Additivity Score: 12.46
  LHighest Single Agent (HSA) Score: 12.48

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Valproic Acid

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[2]
Epilepsy	8A60-8A68	Approved	[2]
Glioblastoma	2A00	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]
Neuroblastoma	2D11.2	Investigative	[2]

Indication(s) of Tolazoline

Disease Entry	ICD 11	Status	REF
Cerebrovascular disease	8B2Z	Approved	[4]
Pulmonary hypertension	BB01	Approved	[5]
Vascular disease	BE2Z	Investigative	[4]

Tolazoline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Valproic Acid FDA Label
• [3] Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.
• [4] Tolazoline FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7310).
• [6] Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31.